POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

Hervé Tilly,Christopher R. Flowers,Jonathan W. Friedberg,Charles Herbaux,Franck Morschhauser,Laurie H. Sehn,Jeff Porter Sharman,Marek Trneny,Calvin Lee,Gilles Salles

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

2019

Hervé Tilly
Christopher R. Flowers
Jonathan W. Friedberg
Charles Herbaux
Franck Morschhauser
Laurie H. Sehn
Jeff Porter Sharman
Marek Trneny
Calvin Lee
Gilles Salles

TPS7571Background: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) remains the standard of care in pts with previously untreated diffuse large B-cell lymphoma (DLBCL) ...

Keywords:

Prednisone
Pathology
Doxorubicin
Polatuzumab vedotin
Lymphoma
Rituximab
Vincristine
CHOP
Oncology
Medicine
Internal medicine
Cyclophosphamide
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations